Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Squamous cell carcinoma of the head and neck


Other Names for this Disease

  • Carcinoma, squamous cell of head and neck
  • Head and neck squamous cell carcinoma
  • HNSCC
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Squamous cell carcinoma of the head and neck. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Cetuximab
Trade Name
(Manufacturer Name)
Erbitux®
(ImClone Systems Incorporated)
Indication
The FDA has approved this product to be used in this manner.
For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Amifostine
Trade Name
(Manufacturer Name)
Ethyol®
(Medimmune Oncology, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.
More Information about this product Drug Information Portal

Other Names for this Disease
  • Carcinoma, squamous cell of head and neck
  • Head and neck squamous cell carcinoma
  • HNSCC
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.